C9 - complement C9 Gene
基因
蛋白
疾病
相关产品
直系同源
中文名称：补体 C9
种属: Homo sapiens
同用名: C9D; ARMD15
基因 ID: 735
|
基因类型: protein coding
关于 C9
Cytogenetic location: 5p13.1
Genomic coordinates (GRCh38): 5:39,284,140-39,364,495 (from NCBI)
This gene has 7 transcripts (splice variants), 190 orthologues, 39 paralogues and is associated with 4 phenotypes. Restricted expression toward liver (RPKM 365.0).
功能概要
该基因编码补体系统的最后一个组成部分。它参与膜攻击复合体 (MAC) 的形成。 MAC 在细菌膜上组装形成一个孔，从而破坏细菌膜组织。该基因的突变会导致 C9 成分缺乏。[RefSeq 提供，2009 年 2 月]
This gene encodes the final component of the Complement System. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on Bacterial membranes to form a pore, permitting disruption of Bacterial membrane organization. Mutations in this gene cause component C9 deficiency. [provided by RefSeq, Feb 2009]
C9 基因产物(1)
mRNA
Protein
Name
NM_001737.5
NP_001728.1
complement component C9 preproprotein
基因本体论
分子功能
生物过程
细胞组分
分子功能 GO 注释
逻辑证据
参考文献
来源
enables protein binding
IPI
IPI: 通过物理相互作用推断
28514442
GOA
生物过程 GO 注释
逻辑证据
参考文献
来源
involved in cell killing
IDA
IDA: 通过直接分析推断
26841934
GOA
involved in protein homooligomerization
IDA
IDA: 通过直接分析推断
26841934
GOA
细胞组分 GO 注释
逻辑证据
参考文献
来源
located in extracellular space
IDA
IDA: 通过直接分析推断
22832194
GOA
part of membrane attack complex
IDA
IDA: 通过直接分析推断
22832194
GOA
part of membrane attack complex
IPI
IPI: 通过物理相互作用推断
30552328
GOA
located in plasma membrane
IDA
IDA: 通过直接分析推断
26841934
GOA
EXP：通过实验结果推断
IDA：通过直接分析推断
IPI：通过物理相互作用推断
IMP：通过突变表型推断
IGI：通过遗传相互作用推断
IEP：通过表达模式推断
C9 蛋白结构
TSP_1
TSP_1: Thrombospondin type 1 domain (46 - 94)
Ldl_recept_a
Ldl_recept_a: Low-density lipoprotein receptor domain class A (100 - 134)
MACPF
MACPF: MAC/Perforin domain (272 - 501)
0
100
200
300
400
500
559 a.a.
蛋白主名
其他名称
complement component C9
complement component 9
C9 蛋白互作信息
分类
蛋白名称
蛋白编号
互作蛋白
互作蛋白种属
互作蛋白编号
实验方法
参考文献
种属内
C9
P02748
APOE
Homo sapiens
P02649
Anti Tag CoIP
33961781
种属内
C9
P02748
APOE
Homo sapiens
P02649
Anti Tag CoIP
28514442
种属间: 跨种属相互作用
种属内: 同种属相互作用
关联疾病
疾病名称
别名
Complement Component 9 Deficiency
C9 Deficiency
C9D
C9 Deficiency With Dermatomyositis
Macular Degeneration, Age-Related, 15
Age Related Macular Degeneration 15
ARMD15
Macular Degeneration, Age-Related, 15, Susceptibility To
Macular Degeneration, Age-Related, Type 15
Immunodeficiency Due To A Late Component Of Complement Deficiency
Immunodeficiency Due To C5 To C9 Component Complement Deficiency
Terminal Complement Pathway Deficiency
Meningococcal Meningitis
Meningitis, Meningococcal
Meningitis Meningococcal
Epidemic Meningitis
Meningitis Due To Neisseria Meningitidis
Meningococcal Meninges Infection
Meningococcal Meningeal Infection
Meningococcal Cerebrospinal Inflammation
Chronic Meningococcal Arachnoiditis
Meningococcal Arachnoiditis
Diplococcal Spinal Meningitis
Diplococcal Meningitis
Meningococcal Cerebrospinal Fever
Meningococcal Cerebrospinal Infection
Meningococcal Spinal Meningitis
Immunoglobulin Heavy-And-Light Chain
Ah/Al Amyloidosis
Ig Heavy-And-Light-Chain Amyloidosis
Eye Disease
Eye Diseases
Abnormality Of The Eye
Toxoplasma Oculopathy
疾病名称
别名
Waldenstroem'S Macroglobulinemia
Waldenstroem'S Macroglobulinemia
Waldenstroem'S Macroglobulinemia
Macroglobulinemia Of Waldenstrom
Lymphoplasmacytic Lymphoma With Igm Gammopathy
Lymphoplasmacytic Lymphoma
Waldenstroem'S Macroglobulinemia
Waldenstroem'S Macroglobulinemia
Macroglobulinemia Of Waldenstrom
Lymphoplasmacytic Lymphoma With Igm Gammopathy
Lymphoplasmacytic Lymphoma
相关产品
Approval
生物活性分子
(9)
目录号
产品名
作用方式
纯度
是否罕见病
HY-17356
Fenofibrate
99.97%
是
HY-N6972
Cepharanthine
99.87%
是
HY-B1218
Sulfaphenazole
Inhibitor
99.85%
否
HY-B0258
Gemfibrozil
99.91%
是
HY-100386
Ticlopidine
Inhibitor
99.74%
否
HY-13463
Avatrombopag
Agonist
99.83%
是
HY-B0153A
Ticlopidine hydrochloride
Inhibitor
99.99%
否
HY-13463A
Avatrombopag maleate
99.88%
是
HY-13463B
Avatrombopag hydrochloride
Agonist
97.05%
是
Clinical Phase
生物活性分子
(9)
目录号
产品名
作用方式
纯度
Phase
HY-132581
Tadnersen
Inhibitor
99.30%
Phase 3
HY-N1201
Apigenin
99.22%
Phase 2
HY-106379
Lurosetron
Antagonist
/
Phase 2
HY-19397
BMS-223131
/
Phase 2
HY-15565
APD668
99.73%
Phase 1
HY-15566
APD597
Agonist
99.97%
Phase 1
HY-12946
BI 653048
Inhibitor
99.84%
Phase 1
HY-114415
AWZ1066S
Inhibitor
98.64%
Phase 1
HY-12946A
BI 653048 phosphate
Inhibitor
/
Phase 1
Pre-clinical Phase
生物活性分子
(207)
Cat. No.
产品名
作用方式
纯度
是否罕见病
HY-N0904
Ginsenoside C-K
Inhibitor
99.93%
否
HY-15550
4'-Hydroxy diclofenac
99.70%
否
HY-15550S
4'-Hydroxy diclofenac-d4
98.92%
否
HY-N0043
Ginsenoside Rd
Inhibitor
99.88%
否
HY-N0893
Tetrahydrocurcumin
98.96%
否
HY-103661
BI-6C9
Inhibitor
98.47%
否
HY-W013268
(S)-(+)-N-3-Benzylnirvanol
Inhibitor
99.54%
否
HY-117026
LKY-047
Inhibitor
99.94%
否
HY-148907
CS640
Inhibitor
96.13%
否
HY-N0920
Dihydrokavain
Inhibitor
99.94%
否
HY-153898
rTRD01
Ligand
99.10%
否
HY-N1446S
Oleic acid-13C
99.99%
否
HY-114759
MS-PPOH
Inhibitor
99.05%
否
HY-100738
Ubiquitin Isopeptidase Inhibitor I, G5
Inducer
98.0%
否
HY-D1422
ER Tracker Yellow
96.91%
否
HY-N0473S3
L-Tyrosine-13C9
99.81%
否
HY-N0911
Rehmannioside A
99.96%
否
HY-100641
4-Hydroxytolbutamide
99.69%
否
HY-117389
Homocarbonyltopsentin
99.82%
否
HY-139345
(S,R,S)-AHPC-CO-C9-acid
Chemical
95.00%
否
HY-N0215S10
L-Phenylalanine-13C9
Antagonist
98.09%
否
HY-W140827
Boc-C9-Br
/
否
HY-157581
MS39
Degrader
99.89%
否
HY-B0158S7
Cytidine-13C9
Chemical
95.0%
否
HY-N1201R
Apigenin (Standard)
98.82%
否
HY-42034
Hydroquinine
99.84%
否
HY-N1050
Zederone
Inhibitor
99.61%
否
HY-W108995
Boc-C9-COOH
/
否
HY-100641S
4-Hydroxytolbutamide-d9
99.29%
否
HY-132581A
Tadnersen sodium
Inhibitor
99.30%
否
HY-14362
GSK-25
Inhibitor
99.68%
否
HY-148822
Nampt activator-2
Activator
98.79%
否
HY-18063
ML252
Inhibitor
99.9%
否
HY-N0215S11
L-Phenylalanine-13C9,15N
Antagonist
99.52%
否
HY-N0688
Linderane
Inhibitor
98.61%
否
HY-128859
EMT inhibitor-2
Inhibitor
98.83%
否
HY-144652
IDO1-IN-19
Inhibitor
98.82%
否
HY-17356R
Fenofibrate (Standard)
99.91%
否
HY-B1449S11
Uridine-13C9
99.00%
否
HY-W751165
Uridine-13C9,15N2
99.0%
否
HY-116862
Dibenzylfluorescein
99.54%
否
HY-113359AS2
Uridine 5'-diphosphate-13C9,15N2 dilithium
Agonist
99.5%
否
HY-125818S3
Cytidine-5'-triphosphate-13C9 dilithium
99.0%
否
HY-B0258R
Gemfibrozil (Standard)
99.90%
否
HY-N7057S3
Nonanoic acid-d2
98.63%
否
HY-N11222
Nonanoylcarnitine
99.87%
否
HY-W013175S2
Uridine 5'-monophosphate-13C9,15N2 disodium
Activator
99.0%
否
HY-B0258S
Gemfibrozil-d6
98.00%
否
HY-107372S2
Uridine triphosphate-13C9 dilithium
98.0%
否
HY-17356S
Fenofibrate-d6
99.70%
否
HY-N1201S
Apigenin-d5
98.90%
否
HY-W009162S5
Cytidine 5′-monophosphate-13C9,15N3 dilithium
99.80%
否
HY-Y0123S
DL-Tyrosine-13C9,15N
98.0%
否
HY-W018801
5-Nitroisoquinoline
99.38%
否
HY-A0070AS1
Liothyronine-13C9,15N
/
否
HY-W009216S1
2'-Deoxycytidine-5'-monophosphate-13C9,15N3 dilithium
99.8%
否
HY-101399S
γ-Glu-(Phe-13C9,15N)
/
否
HY-107372S
Uridine triphosphate-13C9,15N2 sodium
/
否
HY-124352
2-Nonyl-3-hydroxy-4-quinolone
98.0%
否
HY-131495
(S)-6-O-Desmethylnaproxen
Inhibitor
95.73%
否
HY-138527
Thiol-C9-PEG4
99.06%
否
HY-156159
Thalidomide-NH-C9-NH2 hydrochloride
Inducer
99.85%
否
HY-161943
NEU3-IN-1
/
否
HY-170510
GB2095
Inhibitor
98.92%
否
HY-D0184S3
2'-Deoxycytidine-13C9,15N3
99.00%
否
HY-N6023
Thermopsoside
Inhibitor
98.0%
否
HY-N8382
Chalepensin
Inhibitor
98.0%
否
HY-U00048
Bucolome
Inhibitor
98.93%
否
HY-101399SA
γ-Glu-(Phe-13C9,15N) TFA
99.74%
否
HY-117160
4-trans-Hydroxy-glibenclamide
Inhibitor
99.0%
否
HY-132581E
Scrambled Tadnersen
Control
/
否
HY-15550S1
4'-Hydroxy diclofenac-13C6
/
否
HY-159191S
VQPGQN(Phe-13C9,15N)HMFTKEKLEEVIKDI TFA
95.41%
否
HY-W587878
Thujopsene
86.31%
否
HY-W770410
9-PAHSA-13C4
/
否
HY-172177
ROCK/HDAC-IN-2
/
否
HY-135390
Hydroxy desmethyl Bosentan
/
否
HY-100386S
Ticlopidine-d4
Inhibitor
/
否
HY-101400S2
Deoxycytidine triphosphate-13C9,15N3 dilithium
Activator
/
否
HY-101400S4
Deoxycytidine triphosphate-13C9 dilithium
Activator
/
否
HY-101981S3
Uridine 5'-monophosphate-13C9,15N2 dilithium
Activator
/
否
HY-101981S4
Uridine 5'-monophosphate-13C9 dilithium
Activator
/
否
HY-105408A
Fandosentan potassium
/
否
HY-10575
MK-5596
/
否
HY-111906
SCYX-6759
Inhibitor
/
否
HY-113359AS1
Uridine 5'-diphosphate-13C9 dilithium
Agonist
/
否
HY-113400S1
Cytidine diphosphate-13C9 dilithium
/
否
HY-113400S2
Cytidine diphosphate-13C9,15N3 dilithium
99.7%
否
HY-113887
Prostaglandin F1β
Agonist
/
否
HY-113887A
11β-Prostaglandin F1β
Control
/
否
HY-116095
CypD-IN-5
Inhibitor
/
否
HY-116601
6-Hydroxywarfarin
/
否
HY-119781
Kaitocephalin
Antagonist
/
否
HY-119996
AR-C141990
Inhibitor
/
否
HY-13051
SB-773812
Antagonist
/
否
HY-132581C
Scrambled Tadnersen sodium
Control
/
否
HY-13463BS
Avatrombopag-d8 hydrochloride
Agonist
/
否
HY-138517
Thiol-C9-PEG7
/
否
HY-138526
Thiol-C9-PEG4-acid
/
否
HY-138528
Thiol-C9-PEG5-acid
/
否
HY-138529
Thiol-C9-PEG5
/
否
HY-141547
Nav1.7-IN-8
Inhibitor
/
否
HY-141878
di-Ellipticine-RIBOTAC
/
否
HY-141878A
di-Ellipticine-RIBOTAC TFA
/
否
HY-141913S
3-Chlorotyrosine-13C9, 15N hydrochloride
/
否
HY-143906
URAT1 inhibitor 2
Inhibitor
/
否
HY-145490
trans-Hydroxy Glimepiride
/
否
HY-147807
HIV-1 inhibitor-40
Inhibitor
/
否
HY-148597
FGFR-IN-10
Inhibitor
/
否
HY-149566
Thalidomide-5-O-C9-NH2 hydrochloride
Inducer
99.59%
否
HY-149572
Thalidomide-4-O-C9-NH2 hydrochloride
Inducer
99.26%
否
HY-149866
HIV-1 inhibitor-58
Inhibitor
/
否
HY-150710S
Cytidine 5'-triphosphate-13C9,15N3 ammonium
/
否
HY-151251
CYP2C9/CYP2C19-IN-1
Inhibitor
/
否
HY-151253
CYP2C1/CYP2C19-IN-2
Inhibitor
/
否
HY-153371
50-C2-C9-4tail
/
否
HY-153970
URAT1 inhibitor 7
Inhibitor
/
否
HY-155265
Pomalidomide-5-C9-NH2 hydrochloride
98.68%
否
HY-159143
BChE-IN-33
Inhibitor
/
否
HY-160555
(S,R,S)-AHPC-CO-C9-NH2
/
否
HY-160555A
(S,R,S)-AHPC-CO-C9-NH2 hydrochloride
98.79%
否
HY-163208
VH 032 amide-alkylC9-amine hydrochloride
/
否
HY-163816
Antiproliferative agent-53-d3
Inhibitor
/
否
HY-164111
JNK-IN-17
Inhibitor
/
否
HY-166530S
Ticlopidine-d6 hydrochloride
Inhibitor
/
否
HY-166934S
Endosulfan-13C9 sulfate
/
否
HY-167872
Bifeprofen
Inhibitor
/
否
HY-168235
(S,R,S)-AHPC-Me-amide-C9-acid
Degrader
/
否
HY-168277
5-Aminothalidomide-C9-Boc
/
否
HY-169095
(S,R,S)-AHPC-Me-CO-C9-NH2
/
否
HY-171837
c9,t11,c15-CLNA
Activator
/
否
HY-172897
EGFR/DHFR-IN-2
/
否
HY-172902
RNA binder 1
/
否
HY-173032
VU6033685
Agonist
/
否
HY-17356G
Fenofibrate (GMP)
/
否
HY-17356S1
Fenofibrate-d4
/
否
HY-175447
GDC-0152-amide-PEG2-acid
/
否
HY-175887
Pomalidomide-C9-Br
/
否
HY-176737
TGF-β1/Smad-IN-1
Inhibitor
/
否
HY-176905
Tacedinaline-C9-acid
/
否
HY-177070
Angexostat
Inhibitor
/
否
HY-178479
IDO1-IN-30
/
否
HY-178786
RET-IN-31
Inhibitor
/
否
HY-179154
α-Glucosidase-IN-101
Inhibitor
/
否
HY-18341S3
L-Thyroxine-13C9,15N
/
否
HY-79131S1
Fmoc-Phe-OH-13C9,15N
99.33%
否
HY-B0153AS
Ticlopidine-d4 hydrochloride
Inhibitor
/
否
HY-B1422S
9-Aminoacridine-13C6
Inhibitor
/
否
HY-D0184S5
2'-Deoxycytidine-13C9
96.8%
否
HY-N0043R
Ginsenoside Rd (Standard)
Inhibitor
/
否
HY-N0215S9
L-Phenylalanine-13C9,15N,d8
Antagonist
/
否
HY-N0893S
Tetrahydrocurcumin-d6
/
否
HY-N0904R
Ginsenoside C-K (Standard)
Inhibitor
/
否
HY-N1201S1
Apigenin-13C
/
否
HY-P5538S
EPYFGYSGAFK-13C9,15N3 TFA
/
否
HY-P5947
Tat-HA-NR2B9c
/
否
HY-RS00534
AKR1C1 Human Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-RS01759
C9 Human Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-RS01760
C9orf72 Human Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-RS01761
C9orf78 Human Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-RS03460
CYP2C9 Human Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-W008849S
DMT-dC(bz) Phosphoramidite-13C9,15N3
/
否
HY-W009216S4
2'-Deoxycytidine-5'-monophosphate-13C9 dilithium
99.5%
否
HY-W011090S
((2R,3S,4R,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl phosphate-13C9,15N3 sodium
/
否
HY-W015007S
Metyrosine-13C9,15N,d7
Inhibitor
/
否
HY-W018386AS
3-Bromo-L-tyrosine-13C9,15N TFA
/
否
HY-W018386S1
3-Bromo-L-tyrosine-13C9
/
否
HY-W042357S4
Ac-rC Phosphoramidite-13C9
/
否
HY-W042357S6
Ac-rC Phosphoramidite-13C9,15N3
/
否
HY-W048482S1
rU Phosphoramidite-13C9,15N2
/
否
HY-W048482S2
rU Phosphoramidite-13C9
/
否
HY-W127393
N-Nonanoyl-L-homoserine lactone
/
否
HY-W140208
3-Phenylthiophene
Inhibitor
/
否
HY-W707554
Ticlopidine hydrochloride-d6
/
否
HY-W753181
(S)-2-Hydroxy-3-phenylpropanoic acid-13C9
/
否
HY-Z2667
(R)-Esomeprazole
Modulator
/
否
HY-113455S1
9(S)-HODE-13C18
Inducer
/
否
HY-117925
Personalised postprandial-targeting
Inhibitor
/
否
HY-124209
9-keto Fluprostenol
/
否
HY-124352S
2-Nonyl-3-hydroxy-4-quinolone-d4
/
否
HY-134999
10-Hydroxywarfarin
Inhibitor
/
否
HY-150712S
Uridine triphosphate-13C9,15N2 dilithium
/
否
HY-156133
Dihydrospinosyn A aglycone
/
否
HY-164031
Cloperidone
Inhibitor
/
否
HY-169119
Antifungal agent 114
Inhibitor
/
否
HY-169735
Aurora A inhibitor 4
Inhibitor
/
否
HY-170367
Antimicrobial agent-35
Inhibitor
/
否
HY-172335
C9-200
/
否
HY-17356S2
Fenofibrate-13C6
/
否
HY-175169
Urease-IN-21
Inhibitor
/
否
HY-180227
URAT1-IN-15
Inhibitor
/
否
HY-180273
Antibacterial agent 309
Inhibitor
/
否
HY-18063A
ML252 hydrochloride
Inhibitor
/
否
HY-B0158S5
Cytidine-13C9,15N3
98.9%
否
HY-B0258S1
Gemfibrozil-d6-1
/
否
HY-N12962
11S(12R)-EET
/
否
HY-N12962A
11R(12S)-EET
/
否
HY-P0036S3
Octreotide-13C9,15N
/
否
HY-RS17317
C9 Mouse Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-RS20470
Psma4 Mouse Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-RS21991
C9orf72 Mouse Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-RS23772
C9 Rat Pre-designed siRNA Set A
Pre-designed Set
/
否
HY-W008016S
Fmoc-Tyr(tBu)-OH-13C9,15N
98.8%
否
HY-W009162S1
Cytidine 5′-monophosphate-13C9 dilithium
/
否
HY-W440809
Nonyl 8-bromooctanoate
/
否
HY-W800740
Nonyl 6-bromohexanoate
/
否
HY-113623
Pyrenophorol
/
否
抗体抑制剂
(3)
Cat. No.
产品名
作用方式
纯度
是否罕见病
HY-P99141
Anti-Mouse LAG-3 Antibody (C9B7W)
Inhibitor
99%
否
HY-P990140
Anti-Rat β-2-Microglobulin Antibody (4C9)
/
否
HY-P990204
Anti-Mouse LAG-3 (D265A) Antibody (C9B7W)
Inhibitor
/
否
直系同源
种属
基因名
来源
基因 ID
Mus musculus
C9
MGD
MGI:1098282
Felis catus
C9
VGNC
VGNC:60238
Macaca mulatta
C9
VGNC
VGNC:70482
Rattus norvegicus
C9
RGD
RGD:620319
Bos taurus
C9
VGNC
VGNC:26647
Canis familiaris
C9
VGNC
VGNC:38603
Macaca fascicularis
C9
NCBI
NCBI:102137382
Leporidae
C9
NCBI
Others
C9
NCBI
Compound Screening Libraries
实体化合物库
Virtual Screening
虚拟筛选
Customize Your Library
定制专属化合物库
Drug Screening Service
药物筛选服务